Empagliflozin-Loaded Floating Density-Modulated Drug Delivery System as a Novel Approach for Sustained Therapy in Type 2 Diabetes Mellitus with Sodium-Glucose Co-Transporter-2 Inhibition

Authors

  • Arundhati Behera, Vineet Joshi, Rashmi Mohapatra, Dinesh Vishwakarma4, Shreya Sarkar, Sukamal Das, Touseef Begum, Perli. Kranti Kumar Author

DOI:

https://doi.org/10.48047/wsqnzm52

Keywords:

Empagliflozin, Density-modulated drug delivery system (DMDDS), In Vitro Drug Release, Sustained Release, Micromeritic Properties, Type 2 Diabetes

Abstract

The development of a density-modulated drug delivery system (DMDDS) for Empagliflozin aims to enhance 
gastric retention and ensure sustained drug release for effective management of Type 2 Diabetes Mellitus. This 
study evaluated five formulations (EMF1 to EMF5) based on micromeritic properties, weight and drug content 
uniformity, in vitro floatation, and drug release kinetics. Among the formulations, EMF1 demonstrated superior 
flowability, as evidenced by its lowest Carr’s Index (8.49%) and Hausner Ratio (1.09), and the most consistent 
weight uniformity (1.28% CV). Drug content uniformity for EMF1 was exceptionally high (99.98 ± 1.79%), 
ensuring accurate dosing. 

Downloads

Download data is not yet available.

Downloads

Published

2025-02-19

How to Cite

Empagliflozin-Loaded Floating Density-Modulated Drug Delivery System as a Novel Approach for Sustained Therapy in Type 2 Diabetes Mellitus with Sodium-Glucose Co-Transporter-2 Inhibition (Arundhati Behera, Vineet Joshi, Rashmi Mohapatra, Dinesh Vishwakarma4, Shreya Sarkar, Sukamal Das, Touseef Begum, Perli. Kranti Kumar , Trans.). (2025). Cuestiones De Fisioterapia, 54(3), 4357-4368. https://doi.org/10.48047/wsqnzm52